Agenus Inc.

Spencer Campbell

Olga Ignatovich

Benjamin Maxime Morin

Emmanuel Cyrille Pascal Briend

Nicholas Stuart Wilson

Oliver Schon

Jeremy Dale Waight

Dhan Sidhartha Chand

Shawn Michael Jennings

K Mark Bushell

Nicola Anne Ramsay

Zahra Jawad

Beth Wensley

Veronica Franciszka Ilkow

The instant disclosure provides multispecific molecules that specifically bind to CD96 (e.g., human CD96) and/or TIGIT (e.g., human TIGIT) and isolated antibodies that specifically bind to TIGIT (e.g., human TIGIT). Also provided are pharmaceutical compositions comprising these multispecific molecules and antibodies, nucleic acids encoding these multispecific molecules and antibodies, expression vectors and host cells for making these multispecific molecules and antibodies, and methods of treating a subject using these multispecific molecules and antibodies.

Anti-TIGIT and anti-CD96 antibodies

The instant disclosure provides antibodies that specifically bind to CD73 (e.g., human CD73) and antagonize CD73 function. Also provided are anti-CD73 antibodies that further comprise a TGF&#x3b2;-binding moiety or a VEGF-binding moiety. The instant disclosure additionally provides pharmaceutical compositions comprising these antibodies, nucleic acids encoding these antibodies, expression vectors and host cells for making these antibodies, and methods of treating a subject using these antibodies.

Anti-CD73 antibodies and methods of use thereof

Growing community of inventors

Essex, United Kingdom

Spencer Campbell